Douglas Grossman, MD, PhD, is an investigator in Huntsman Cancer Institute's (HCI) Melanoma Program and a Professor in the Department of Dermatology at the University of Utah School of Medicine. He is Co-Leader of the Melanoma center at HCI. He sees patients at risk for melanoma and non-melanoma skin cancer, with a special interest in patients who have a personal or family history of melanoma; numerous and/or atypical moles (nevi); a personal history of basal or squamous cell carcinoma; or a history of excessive sun exposure. Grossman had directed the Mole Mapping Program at HCI since 2004.
Grossman's lab studies mechanisms of tumor development and metastasis in melanoma. In addition, they study the role of UV-induced oxidative stress and DNA damage using human nevi (moles) as a model system. They are using this knowledge to develop novel chemopreventive agents for patients at increased risk for melanoma.
Grossman received his MD and PhD from Baylor College of Medicine, completed an internship at Yale-New Haven Hospital, and completed a dermatology residency at Yale. He remained at Yale for a research fellowship in cancer biology, and then joined Huntsman Cancer Institute and the University of Utah School of Medicine faculty in 2001.
Douglas Grossman, MD, PhD, is an expert in the early diagnosis and treatment of skin cancers. He received his medical degree from Baylor College of Medicine in 1994, and completed his dermatology training at Yale University School of Medicine in 1998. Following a research fellowship in cancer biology at Yale, he was recruited to the University of Utah in 2001. He sees patients with a personal history of skin cancer or excessive sun exposure, and those at increased risk for melanoma who may have numerous or atypical moles or family members with melanoma. He directs the Mole Mapping Program at the Huntsman Cancer Institute.